What is the management for a 34-year-old female with esophageal spasm after passing a clot, negative pregnancy test, and normal lab results (within normal limits, WNL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Esophageal Spasm in a 34-Year-Old Female

Start with calcium channel blockers (diltiazem 30-60 mg before meals) or long-acting nitrates (isosorbide dinitrate 5-10 mg before meals) as first-line pharmacotherapy, and if symptoms persist after 4-6 weeks, proceed to endoscopic botulinum toxin injection into the distal esophageal body. 1, 2, 3

Initial Diagnostic Workup

  • Perform high-resolution esophageal manometry to confirm the diagnosis of distal esophageal spasm, defined by premature contractions with distal latency <4.5 seconds in the context of normal lower esophageal sphincter relaxation. 1, 4

  • Obtain upper endoscopy with biopsies (minimum 5 samples) to exclude alternative diagnoses including eosinophilic esophagitis, GERD-related complications, or structural abnormalities, particularly given the history of passing a clot which raises concern for mucosal injury. 1

  • Rule out cardiac causes of chest pain before attributing symptoms to esophageal spasm, as this is a critical pitfall—coronary artery disease must be excluded in any patient presenting with chest pain. 1

Pharmacological Management Algorithm

First-Line Therapy (4-6 week trial)

  • Calcium channel blockers (diltiazem 30-60 mg or nifedipine 10-20 mg before meals) reduce esophageal contractile force and show manometric improvement, though clinical benefit varies. 3, 4

  • Nitrates (short-acting sublingual nitroglycerin for acute episodes; long-acting isosorbide dinitrate 5-10 mg before meals for maintenance) work through nitric oxide-mediated smooth muscle relaxation. 3, 4

  • Proton pump inhibitors twice daily should be initiated empirically, as GERD frequently coexists with esophageal spasm and may contribute to symptom pathogenesis. 1, 4

Second-Line Therapy

  • Tricyclic antidepressants (such as imipramine 25-50 mg at bedtime, titrated up to 100 mg) or SSRIs serve as visceral analgesics and address the psychological component often present in esophageal motility disorders. 3, 4, 5

  • Psychological evaluation is warranted as 56% of esophageal spasm patients have major psychiatric disorders (anxiety, depression), and antidepressants showed 89% improvement rates in one prospective study. 5

Third-Line Therapy

  • Endoscopic botulinum toxin injection (100 IU diluted in 10 mL saline, injected at multiple sites along the distal esophageal wall in 1-1.5 cm intervals starting from the lower esophageal sphincter) provides 78-89% immediate symptom improvement with effects lasting 6-24 months. 2, 6

  • Repeat botulinum toxin injections are effective for symptom relapse, with similarly good results upon retreatment. 6

Surgical Considerations

  • Reserve Heller myotomy with fundoplication for the rare patient with severe, refractory symptoms unresponsive to all medical and endoscopic therapies. 4

  • Per-oral endoscopic myotomy (POEM) represents an emerging alternative endoscopic technique, though long-term data are limited. 4

Critical Clinical Pitfalls

  • Do not dismiss the "passing clot" history—this warrants endoscopic evaluation to exclude mucosal injury, esophageal perforation, or bleeding lesions that could masquerade as or coexist with esophageal spasm. 1

  • Avoid attributing all chest pain to esophageal spasm without cardiac workup, as this represents a dangerous missed diagnosis. 1

  • Recognize that medical therapy alone is often disappointing—only a subset of patients achieve meaningful clinical improvement despite manometric improvements, necessitating progression through the treatment algorithm. 3

  • Monitor for progression to achalasia, as small case series suggest esophageal spasm can evolve into achalasia over time. 4

Follow-Up Strategy

  • Reassess symptoms at 4-6 weeks after initiating pharmacotherapy to determine response and need for escalation. 3, 4

  • Consider repeat manometry if symptoms persist despite treatment to evaluate for disease progression or alternative diagnoses. 1

  • Screen for psychological comorbidities including anxiety and depression, as these substantially impact symptom perception and treatment response. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Botulinum toxin in the treatment of diffuse esophageal spasm.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2010

Research

Esophageal pharmacology and treatment of primary motility disorders.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 1999

Research

Distal esophageal spasm: an update.

Current gastroenterology reports, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.